Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul:187:105-113.
doi: 10.1016/j.ejca.2023.03.028. Epub 2023 Mar 31.

European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care

Fatima Cardoso  1 , Amelia McCartney  2 , Antonio Ponti  3 , Lorenza Marotti  4 , Conny Vrieling  5 , Alexandru Eniu  6 , Berta Sousa  7 , Carla Ripamonti  8 , Luzia Travado  7 , Sabine Spitz  9 , Eva Jolly  10 , Giuseppe Curigliano  11 , Frederique Penault-Llorca  12 , Frederic Lecouvet  13 , Isabel T Rubio  14 , Laura Biganzoli  15
Affiliations

European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care

Fatima Cardoso et al. Eur J Cancer. 2023 Jul.

Abstract

Aims: Improvement in the care of patients with metastatic breast cancer (MBC) can only occur if the adequate quality of care is implemented and verified, including access to multidisciplinary, specialised care given in accordance with high-quality guidelines. To this purpose, European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance joined efforts to develop the first set of quality indicators (QI) specifically for MBC that should be routinely measured and evaluated to ensure that breast cancer centres meet the required standards.

Methods: A working group of multidisciplinary European experts in breast cancer met to discuss each identified QI, reporting the definition, the minimum and target standard for breast cancer centres to achieve, and the motivation for selection. The level of evidence was determined according to the short version of the United States Agency for Healthcare Research and Quality classification.

Results: QI to measure access to and involvement in multidisciplinary and supportive care, appropriate pathological characterisation of disease, systemic therapies and radiotherapy were developed with the consensus of the working group.

Conclusions: This is the first effort of a multistep project that aims to have QI for MBC routinely measured and evaluated to ensure that breast cancer centres achieve mandated standards in the care of patients with metastatic disease.

Keywords: Advanced breast cancer; Metastatic breast cancer; Multidisciplinary care; Outcome; Quality control; Quality indicators; Quality of cancer care; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Fatima Cardoso: consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime. None in relation with this article. Amelia McCartney: advisory board of the Limbic Oncology online publication. None in relation with this article. Alexandru Eniu: Receipt of grants/research supports from Astra Zeneca, Roche, Celltrion, Pfizer, Novartis. None in relation with this article. Antonio Ponti, Lorenza Marotti, Conny Vrieling, Berta Sousa, Luzia Travado, Sabine Spitz, Giuseppe Curigliano, Frederique Penault-Llorca and Eva Jolly have no disclosures to declare. Laura Biganzoli: consultancy role for AstraZeneca, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Seattle Genetics. Receipt research supports from Celgene, Genomic Health, Novartis. None in relation with this article. Carla Ripamonti: receipt of honorarium from Molteni, Angelini, Kyowa Kyrin and Mundipharma for educational programs (preparation of booklets and speaker). Isabel T. Rubio: honoraria from Sirius, Roche and Astra-Zeneca (from lectures). Frederic Lecouvet: receipt of grants/research support from GE healthcare, not in relation with this article. The European School of Oncology is an ABC Global Alliance funding member. It is sponsored through unrestricted grants and sponsorships provided by AstraZeneca, BMS, Gilead, Novartis, MSD, Pfizer, Sanofi. None in relation with this article. The ABC Global Alliance is grateful for the pro-bono services and contributions to some of its events and initiatives by Novobanco and PLMJ. None in relation with this article.

LinkOut - more resources